MERTK is a member of the TAM (TYRO3, AXL, and MERTK) family RTKs that is overexpressed or ectopically expressed in about 70% of NSCLCs and is an attractive biologic target for treatment of NSCLC (25, 26). Here, AXL is linked to non-small cell lung carcinoma.